Shots:

• The FDA has approved eXciteOSA to treat mild obstructive sleep apnea and snoring by using for only 20 min./day for a period of 6 wks. and then twice per week
• In a study of 65 mild obstructive sleep apnea patients- 79% responded to therapy with 52% mean reduction in AHI- 50% reduction in ODI- 3.9point reduction in ESS. In a pivotal study- eXciteOSA achieved nearly a 40% reduction in snoring time across 115 patients
• eXciteOSA is the first and only daytime intraoral neuromuscular stimulation device for treating mild obstructive sleep apnea and snoring will be available in the US imminently

 ­ Ref: Businesswire | Image: Businesswire